Considerations in the management of the patient with PV. Baseline PV risk, patient features, choice of cytoreduction, patient goals, and topical issues such as the COVID-19 pandemic need to be integrated in the treatment decision-making process. *Tolerability not only refers to drug-specific toxicity profiles but also therapy-related iatrogenesis of disease-related issues such as worsening of iron deficiency and hemorrhage. PV, polycythemia vera. QOL, quality of life.